0000899243-20-014618.txt : 20200529
0000899243-20-014618.hdr.sgml : 20200529
20200529191716
ACCESSION NUMBER: 0000899243-20-014618
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200527
FILED AS OF DATE: 20200529
DATE AS OF CHANGE: 20200529
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HAUMANN BRETT K
CENTRAL INDEX KEY: 0001607733
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37519
FILM NUMBER: 20930307
MAIL ADDRESS:
STREET 1: 901 GATEWAY BLVD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aimmune Therapeutics, Inc.
CENTRAL INDEX KEY: 0001631650
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 452748244
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8000 MARINA BOULEVARD
STREET 2: SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005-1884
BUSINESS PHONE: (650) 614-5220
MAIL ADDRESS:
STREET 1: 8000 MARINA BOULEVARD
STREET 2: SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005-1884
FORMER COMPANY:
FORMER CONFORMED NAME: Allergen Research Corp
DATE OF NAME CHANGE: 20150123
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-05-27
0
0001631650
Aimmune Therapeutics, Inc.
AIMT
0001607733
HAUMANN BRETT K
AIMMUNE THERAPEUTICS, INC.
8000 MARINA BOULEVARD, SUITE 300
BRISBANE
CA
94005-1884
1
0
0
0
Common Stock, $0.0001 par value
2020-05-27
4
A
0
13313
0.00
A
19563
D
Stock Option (right to buy)
17.11
2020-05-27
4
A
0
25453
0.00
A
2030-05-26
Common Stock
25453
25453
D
These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest as to 1/3rd of the RSUs on each anniversary of the grant date, assuming continuous service as a director until each such vesting date.
The shares subject to the option will vest and become exercisable as to 1/36th of the shares subject to the option on each monthly anniversary of the grant date, assuming continuous service as a director until each such vesting date.
/s/ Douglas T. Sheehy, as Attorney-in-Fact for Brett K. Haumann
2020-05-29